Several weeks ago, Cathie Wood's ARK Fund ARKG invested in the biotech psychedelics sector, specifically in major player Atai Life Sciences ATAI.
The first purchase took place in February 2022, when ARK bought 83,278 shares of Atai Life Sciences. Less than two weeks later, the company acquired four times that, bringing its total ownership to over 340,000 shares, as first reported by Jason Najum on Microdose.
In early July 2022, the company’s spreadsheet showed it held a total 1,827,047 of Atai’s shares -representing an increase of more than 138,000 shares from March 2022.
By mid-July, the total monthly investment was 621,812 shares. Yet ARK further acquired shares. Now it can be said that the total purchase of Atai stock for that month is over 3 million (3,018,751).
Considering its rounding $4 for July, that’s $12 million invested in psychedelics by Cathie Wood’s fund, aka a noteworthy purchase from a celebrity investor.
Photo Courtesy of Jeffrey Blum on Unsplash.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!